Related Experiment Video
Updated: Sep 30, 2025
Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
Published on: September 15, 2023
Integrated Bioinformatics Analysis and Validation of the Prognostic Value of RBM10 Expression in Hepatocellular
Shu-Jie Pang1, Zhe Sun1, Wen-Feng Lu1
1Department V of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, 200438, People's Republic of China.
Insights
The RNA-binding protein 10 (RBM10) is a poor prognostic factor in hepatocellular carcinoma (HCC). High RBM10 expression correlates with advanced tumor stage and poor survival, suggesting its potential as an immunotherapy biomarker in HCC.
Area of Science:
- Oncology
- Molecular Biology
- Immunology
Background:
- The role of RNA-binding protein 10 (RBM10) in hepatocellular carcinoma (HCC) is underexplored.
- Investigating RBM10's prognostic and therapeutic significance in HCC is crucial.
Purpose of the Study:
- To analyze the expression status and prognostic value of RBM10 in HCC.
- To explore the relationship between RBM10 and clinical features, and its role in immune infiltration.
Main Methods:
- Utilized multiple databases to analyze RBM10 expression and survival in HCC.
- Performed enrichment analyses and constructed a protein-protein interaction network.
- Validated prognostic value using immunohistochemistry in an HCC cohort.
Main Results:
- RBM10 mRNA levels positively correlated with tumor grade, T classification, and stage.
- High RBM10 expression predicted poor overall and recurrence-free survival in HCC patients.
- RBM10 is implicated in cell cycle, DNA replication, and immune pathways, and correlates with immune cell infiltrates and PD-1/PD-L1 expression.
Conclusions:
- RBM10 serves as a poor prognostic factor in HCC.
- RBM10 may act as a potential biomarker for immunotherapy in HCC due to its involvement in immune-related pathways.
Background:
RBM10's function in hepatocellular carcinoma (HCC) has rarely been addressed. We intend to explore the prognostic significance and therapeutic meaning of RBM10 in HCC in this study.
Methods:
Multiple common databases were integrated to analyze the expression status and prognostic meaning of RBM10 in HCC. The relationship between RBM10 mRNA level and clinical features was also assessed. Multiple enrichment analyses of the differentially expressed genes between RBM10 high- and low- transcription groups were constructed by using R software (version 4.0.2). A Search Tool for Retrieval of Interacting Genes database was used to construct the protein-protein interaction network between RBM10 and other proteins. A tumor immune estimation resource database was employed to identify the relationship between RBM10 expression and immune cell infiltrates. The prognostic value of RBM10 expression was validated in our HCC cohort by immunohistochemistry test.
Results:
The transcription of RBM10 mRNA was positively correlated with tumor histologic grade (p < 0.001), T classification (p < 0.001), and tumor stage (p < 0.001). High transcription of RBM10 in HCC predicted a dismal overall survival (p = 0.0037) and recurrence-free survival (p < 0.001). Kyoto Encyclopedia of Genes and Genomes, Gene Ontology, and Gene Set Enrichment Analysis all revealed that RBM10 was involved in the regulation of cell cycle, DNA replication, and immune-related pathways. Tumor immune estimation analysis revealed that RBM10 transcription was positively related to multiple immune cell infiltrates and the expressions of PD-1 and PD-L1.
Conclusion:
RBM10 was demonstrated to be a dismal prognostic factor and a potential biomarker for immune therapy in HCC in that it may be involved in the immune-related signaling pathways.
More Related Videos
07:41Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases
Published on: May 17, 2019
07:32Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
Published on: April 12, 2024
